GlaxoSmithKline quells market concerns for now but hard work yet to startProactive Investors • 06/24/21
GlaxoSmithKline: Did CEO's revamp plan pass City muster? One leading bank has its sayProactive Investors • 06/24/21
GSK unveils ambitious growth targets after pressure from activist fund Elliott. But is this enough?Market Watch • 06/23/21
Crunch time for GSK on Wednesday; Berkeley to report on London housing exodusProactive Investors • 06/22/21
Crunch time for GSK on Wednesday with Berkeley and PMI readings bringing up the rearProactive Investors • 06/22/21
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme DealBenzinga • 06/22/21
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIVPRNewsWire • 06/22/21
GlaxoSmithKline CEO Struggling To Get Key Shareholders In Her Favor Amid Pressure From Hedge Fund Activist Elliott ManagementBenzinga • 06/21/21
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 PatientsBenzinga • 06/21/21
GlaxoSmithKline share price surge keeps Emma Walmsley's head above water, but for how long?Proactive Investors • 06/21/21